1,2-diethyl-1H-imidazole | 51807-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,2-diethyl-1H-imidazole
• 英文别名: 1,2-Diaethyl-1H-imidazol；1,2-Diaethylimidazol；1,2-Diethyl-1H-imidazole；1,2-diethylimidazole
• CAS: 51807-53-5
• 化学式: C₇H₁₂N₂
• 分子量: 124.186
• InChiKey: OQSQRYMTDPLPNY-UHFFFAOYSA-N

物化性质

• 沸点：
  221°C (rough estimate)
• 密度：
  0.9813

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,2-diethyl-1H-imidazole 、 双氧水 生成 ethyl-oxalamide
  参考文献：
  名称：

  Radziszewski, Chemische Berichte, 1884, vol. 17, p. 1289

  摘要：

  DOI：
• 作为产物：
  描述：

  2-Ethyl-imidazole-1-carboxylic acid ethyl ester 以65%的产率得到
  参考文献：
  名称：

  LOOZEN H. J. J.; DROUEN J. J. M.; PIEPERS O., J. ORG. CHEM. , 1975, 40, NO 22, 3279-3280

  摘要：

  DOI：

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20170217974A1

  公开（公告）日：2017-08-03

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I）或其药学上可接受的盐、酯或前药： X-A-Y-Z-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• [EN] PIPERAZINE-SUBSTITUTED 7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES<br/>[FR] COMPOSÉS DE 7-MÉTHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLINE-5-AMINE À SUBSTITUTION PIPÉRAZINE PRÉSENTANT DES PROPRIÉTÉS D'ANTAGONISTE D'A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2014101113A1

  公开（公告）日：2014-07-03

  Disclosed are compounds of Formula (A), as defined herein, which have binding activity for an A2A-receptor and are believed to be useful for treatment or management of CNS diseases or conditions which can be treated or managed using compounds which have A2A receptor antagonist activity.

  本公开的是本文所定义的Formula (A)的化合物，它们具有与A2A受体的结合活性，并被认为对于治疗或管理可以使用具有A2A受体拮抗活性的化合物来治疗或管理的中枢神经系统疾病或疾况是有用的。
• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• Inhibitors of protein tyrosine kinase activity
  申请人：Raeppel Stephane

  公开号：US20080004273A1

  公开（公告）日：2008-01-03

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  这项发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，该发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，导致受体信号传导的抑制，例如抑制VEGF受体信号传导和HGF受体信号传导。更具体地，该发明涉及用于抑制VEGF受体信号传导和HGF受体信号传导的化合物、组合物和方法。该发明还提供了用于治疗细胞增殖性疾病和病况的组合物和方法。
• One-step process for the preparation of halide-free hydrophobic salts
  申请人：——

  公开号：US20040225131A1

  公开（公告）日：2004-11-11

  This invention describes a one pot, single-step process for the preparation of halide-free hydrophobic salts comprising polyalkylated imidazolium cations and various anions in accordance with the following structure, where R 1 and R 3 represent the either the same or different alkyl groups, and R 2 , R 4 , and R 5 represent either hydrogen atoms, or the same or different alkyl group substituents; X represents a polyatomic anion that is the conjugate base of an acid. By simply mixing aqueous formaldehyde with an alkyl amine such as methylanune, ethylamine, n-propyl oriso-propylamine, or n-butyl-, iso-butyl, or t-butylamine, or by mixing aqueous formaldehyde with two alkyl amines (preferably one being methylamine, ethylamine, n-propyl- or iso-propylamine, or n-butyl-, isobutyl, or t-butylamine) and another being n-propyl- or isopropylaine, or n-butyl-, isbutyl, or t-butylamine), an acid (such as hexafluorophosphoric acid, trifluoroacetic acid, pentafluoropropionic, heptafluorobutyric acid, or the free acid of a bis(perfluoroalkylsulfonyprnide or tris(perfluoroalkylsulfonyl)methide as the source of the anion) and aqueous glyoxal solution, the hydrophobic ionic salts or mixtures thereof thus formed may be conveniently separated directly from the aqueous byproduct layer. Like the single cation hydrophobic salts, these mixed hydrophobic ionic liquids are non-flammable and manifest no detectable vapor pressure up to their decomposition temperature of greater than 300° C. We have also discovered that, surprisingly, ternary mixtures of dialkylated ionic liquids manifest higher ionic conductivities than a single ionic liquid of the mixture alone. This property benefits electrochemical power source applications such as batteries and capacitors. Furthermore, we have discovered that ternary mixtures of dialkylated ionic liquids absorb microwave radiation more efficiently than a single ionic liquid of the mixture alone. This property benefits microwave-induced synthetic reactions. Such physical and chemical properties make it possible to employ inexpensive mixtures of polyalkylated imidazolium cations in an advantageous manner as thermal transfer fluids, high temperature lubricants, and plasticizers, and as solvents in the areas of electrochemistry, synthetic chemistry, catalysis, and separations chemistry. 1

  这项发明描述了一种一锅法、单步骤的制备无卤疏水盐的过程，包括具有多取代咪唑阳离子和各种阴离子的结构，其中R1和R3代表相同或不同的烷基基团，R2、R4和R5代表氢原子或相同或不同的烷基基团取代物；X代表是酸的共轭碱的多原子阴离子。通过简单地混合水甲醛与烷基胺（如甲基胺、乙基胺、正丙基或异丙基胺、正丁基、异丁基或叔丁基胺）或混合水甲醛与两种烷基胺（最好是一种为甲基胺、乙基胺、正丙基或异丙基胺、正丁基、异丁基或叔丁基胺，另一种为正丙基或异丙基胺、正丁基、异丁基或叔丁基胺）、酸（如六氟磷酸、三氟乙酸、五氟丙酸、七氟丁酸，或作为阴离子源的双（全氟烷基磺酰基）或三（全氟烷基磺酰基）甲烷的游离酸）和水甘醛溶液，因此形成的疏水离子盐或其混合物可以方便地直接从水相副产物层分离出来。像单阳离子疏水盐一样，这些混合疏水离子液体是不可燃的，并且在其分解温度高于300°C时没有可检测到的蒸汽压力。我们还发现，令人惊讶的是，二烷基化离子液体的三元混合物表现出比单一混合物中的离子液体更高的离子电导率。这种性质有益于电化学动力源应用，如电池和电容器。此外，我们还发现，二烷基化离子液体的三元混合物比单一混合物中的离子液体更有效地吸收微波辐射。这种性质有益于微波诱导的合成反应。这些物理和化学性质使得可以以有利的方式将廉价的多取代咪唑阳离子混合物用作热传输流体、高温润滑剂和增塑剂，并作为电化学、合成化学、催化和分离化学领域的溶剂。